I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3891人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088849, encodeId=e98f2088849c4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, objectType=article, longId=206516, objectId=fdf420651685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf420651685, replyNumber=0, likeNumber=55, createdTime=2021-10-06, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf420651685, moduleTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdf420651685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088834, encodeId=398020888340e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, objectType=article, longId=202651, objectId=9ce020265159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ce020265159, replyNumber=0, likeNumber=68, createdTime=2021-05-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ce020265159, moduleTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ce020265159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088842, encodeId=0b3320888428d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, objectType=article, longId=203861, objectId=324020386153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=324020386153, replyNumber=0, likeNumber=71, createdTime=2021-08-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=324020386153, moduleTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=324020386153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088826, encodeId=a3882088826c3, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, objectType=article, longId=201330, objectId=7e8920133089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e8920133089, replyNumber=0, likeNumber=75, createdTime=2021-06-18, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e8920133089, moduleTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e8920133089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088840, encodeId=6168208884026, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, objectType=article, longId=203277, objectId=fdc22032e7e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdc22032e7e0, replyNumber=0, likeNumber=0, createdTime=2020-12-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdc22032e7e0, moduleTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdc22032e7e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088839, encodeId=63b1208883912, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, objectType=article, longId=203254, objectId=0697203254d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0697203254d7, replyNumber=0, likeNumber=80, createdTime=2021-02-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0697203254d7, moduleTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0697203254d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088835, encodeId=ce6020888359c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, objectType=article, longId=202653, objectId=fcf72026535d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcf72026535d, replyNumber=0, likeNumber=65, createdTime=2021-10-01, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcf72026535d, moduleTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcf72026535d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088861, encodeId=f3b6208886159, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, objectType=article, longId=209884, objectId=8e3c20988469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3c20988469, replyNumber=0, likeNumber=42, createdTime=2022-03-17, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3c20988469, moduleTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3c20988469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088848, encodeId=ba5e208884818, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=济民可信新冠病毒特异性中和抗体JMB2002启动I期临床试验, objectType=article, longId=206287, objectId=c78320628e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78320628e43, replyNumber=0, likeNumber=31, createdTime=2021-02-04, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78320628e43, moduleTitle=济民可信新冠病毒特异性中和抗体JMB2002启动I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c78320628e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088853, encodeId=ce33208885344, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=IkT-148009治疗帕金森，I期临床试验已正式开始, objectType=article, longId=207290, objectId=56ba20e290d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56ba20e290d4, replyNumber=0, likeNumber=57, createdTime=2021-11-05, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56ba20e290d4, moduleTitle=IkT-148009治疗帕金森，I期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56ba20e290d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088823, encodeId=da352088823fd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=87, createdTime=2020-10-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088806, encodeId=93972088806ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, objectType=article, longId=194690, objectId=fbb4194690aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbb4194690aa, replyNumber=0, likeNumber=56, createdTime=2020-09-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbb4194690aa, moduleTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbb4194690aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088828, encodeId=1b19208882864, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, objectType=article, longId=201506, objectId=3857201506d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3857201506d7, replyNumber=0, likeNumber=60, createdTime=2020-12-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3857201506d7, moduleTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3857201506d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088814, encodeId=368820888148e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, objectType=article, longId=197670, objectId=9e0019e6706c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0019e6706c, replyNumber=0, likeNumber=111, createdTime=2020-12-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0019e6706c, moduleTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0019e6706c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088829, encodeId=5e8b2088829b7, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, objectType=article, longId=201543, objectId=a72820154315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72820154315, replyNumber=0, likeNumber=103, createdTime=2020-10-18, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72820154315, moduleTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72820154315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088824, encodeId=53f6208882452, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Nat Commun：I期临床试验: 全反式视黄酸作为胰腺癌基质靶向药物, objectType=article, longId=201294, objectId=651520129438, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=651520129438, replyNumber=0, likeNumber=65, createdTime=2021-08-01, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=651520129438, moduleTitle=Nat Commun：I期临床试验: 全反式视黄酸作为胰腺癌基质靶向药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=651520129438)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088811, encodeId=eeac2088811ab, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, objectType=article, longId=196221, objectId=32501962219e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32501962219e, replyNumber=0, likeNumber=72, createdTime=2021-04-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32501962219e, moduleTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32501962219e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088804, encodeId=1bce208880472, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=77, createdTime=2020-12-17, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088833, encodeId=5a8f208883325, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据, objectType=article, longId=202473, objectId=2a172024e33a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a172024e33a, replyNumber=0, likeNumber=106, createdTime=2021-03-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a172024e33a, moduleTitle=GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a172024e33a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088791, encodeId=8c412088e91c1, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, objectType=article, longId=190693, objectId=7c61190693ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c61190693ac, replyNumber=0, likeNumber=77, createdTime=2021-01-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c61190693ac, moduleTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c61190693ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募

2021-10-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果

2021-05-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验

2021-08-10

一叶知秋 (审核中...)

前往app查看评论内容

#I期临床试验#

雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验

2021-06-18

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验

2020-12-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

JAHA：二甲双胍治疗肺动脉高压的II期临床试验

2021-02-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验

2021-10-01

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性

2022-03-17

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

济民可信新冠病毒特异性中和抗体JMB2002启动I期临床试验

2021-02-04

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

IkT-148009治疗帕金森，I期临床试验已正式开始

2021-11-05

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2020-10-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验

2020-09-10

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Xevinapant治疗头颈癌：步入大型III期临床试验

2020-12-30

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验

2020-12-30

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验

2020-10-18

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Nat Commun：I期临床试验: 全反式视黄酸作为胰腺癌基质靶向药物

2021-08-01

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验

2021-04-30

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-12-17

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据

2021-03-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展

2021-01-12

科室
- - 订阅+
  - 更多科室
工具
服务